ACH
RLAY icon

ArrowMark Colorado Holdings’s Relay Therapeutics RLAY Stock Holding History

ArrowMark Colorado Holdings’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Hold
541,124
– – 0.42% 88
2026
Q1 		$5.38M Hold
541,124
– – 0.14% 170
2025
Q4 		$4.58M Hold
541,124
– – 0.1% 203
2025
Q3 		$2.82M Hold
541,124
– – 0.05% 217
2025
Q2 		$1.87M Hold
541,124
– – 0.03% 232
2025
Q1 		$1.42M Hold
541,124
– – 0.02% 239
2024
Q4 		$2.23M Hold
541,124
– – 0.03% 227
2024
Q3 		$3.83M Hold
541,124
– – 0.05% 205
2024
Q2 		$3.53M Sell
541,124
-3,464,046
-86% -$23.7M 0.04% 225
2024
Q1 		$33.2M Buy
4,005,170
+90,924
+2% +$887K 0.37% 72
2023
Q4 		$43.1M Buy
3,914,246
+103,667
+3% +$875K 0.48% 63
2023
Q3 		$32M Buy
3,810,579
+391,910
+11% +$4.21M 0.39% 75
2023
Q2 		$42.9M Buy
3,418,669
+748,472
+28% +$9.31M 0.47% 69
2023
Q1 		$44M Sell
2,670,197
-16,514
-0.6% -$296K 0.5% 60
2022
Q4 		$40.1M Buy
2,686,711
+174,243
+7% +$3.34M 0.48% 66
2022
Q3 		$56.2M Sell
2,512,468
-328,205
-12% -$7.2M 0.69% 48
2022
Q2 		$47.6M Buy
2,840,673
+815,559
+40% +$17.5M 0.54% 61
2022
Q1 		$60.6M Sell
2,025,114
-8,210
-0.4% -$199K 0.53% 58
2021
Q4 		$62.4M Buy
2,033,324
+1,590,591
+359% +$50.3M 0.5% 61
2021
Q3 		$14M Buy
442,733
+70,538
+19% +$2.37M 0.11% 155
2021
Q2 		$13.6M Buy
372,195
+32,759
+10% +$1.08M 0.1% 164
2021
Q1 		$11.7M Sell
339,436
-841
-0.2% -$36.5K 0.09% 181
2020
Q4 		$14.1M Sell
340,277
-4,677
-1% -$211K 0.11% 144
2020
Q3 		$14.7M Buy
+344,954
New +$13.2M 0.14% 120

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

ArrowMark Colorado Holdings's RLAY Position: Q2 2026 in Review

ArrowMark Colorado Holdings held its Relay Therapeutics (RLAY) position steady in Q2 2026 at 541,124 shares worth $10.1M. The position accounts for 0.42% of the portfolio, ranked #88.

ArrowMark Colorado Holdings first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. The position peaked at $62.4M in Q4 2021. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • ArrowMark Colorado Holdings held 541,124 shares of Relay Therapeutics worth $10.1M as of Q2 2026.
  • ArrowMark Colorado Holdings left its Relay Therapeutics share count unchanged in Q2 2026.
  • Relay Therapeutics made up 0.42% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #88 holding.
  • ArrowMark Colorado Holdings first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • ArrowMark Colorado Holdings's Relay Therapeutics position peaked at $62.4M in Q4 2021.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.